实时肿瘤追踪SBRT治疗I-IIA期非小细胞肺癌的临床结局
多中心回顾性研究纳入283例I-IIA期周围型NSCLC患者(286个肿瘤),采用实时肿瘤追踪(RTRT)系统行SBRT,中位随访28个月。全组2年、3年总生存率分别为75%、64%;2级和3级放射性肺炎发生率分别为10.2%和3.2%,无4-5级事件。GTV至PTV外扩<10 mm未降低生存与局部控制,且减少放射性肺炎风险。
要点
- RTRT引导SBRT治疗早期周围型NSCLC的2年、3年总生存率分别为75%、64%。
- 2级和3级放射性肺炎发生率分别为10.2%和3.2%,未发生4-5级放射性肺炎。
- GTV至PTV外扩<10 mm未恶化生存与局部控制,并降低放射性肺炎风险。
核心结论
- 多中心回顾性研究显示,RTRT系统引导SBRT治疗I-IIA期周围型NSCLC的结局与近期SBRT照护模式和结局分析一致。
- GTV至PTV外扩<10 mm不 worsen 总生存和局部控制,同时降低放射性肺炎风险,但需前瞻性研究验证。
研究设计与样本
- 四家机构参与的多中心回顾性研究,采用统一临床报告格式分析SBRT照护模式和结局模式。
- 2000年9月至2012年4月纳入283例组织学证实、周围型、I期和IIA期NSCLC患者,共286个肿瘤。
- 中位年龄78岁(范围52-90岁),最大肿瘤直径9-65 mm(中位24 mm)。
- 等中心生物有效剂量(10)按线性二次模型计算为66-126 Gy(中位106 Gy),中位随访28个月(范围0-127个月)。
主要发现
- 全组2年、3年总生存率分别为75%、64%;IA期分别为79%、70%;IB+IIA期分别为65%、50%。
- 多因素分析中,女性是总生存的有利预测因素。
- 四家机构间的临床结局无差异。
- 2级、3级、4级、5级放射性肺炎分别发生于29例(10.2%)、9例(3.2%)、0例、0例。
- 亚组分析显示,与GTV至PTV外扩≥10 mm相比,外扩<10 mm未 worsening 总生存和局部控制率,同时降低放射性肺炎风险。
关键数值与推荐
- 等中心生物有效剂量(10)范围为66 Gy至126 Gy,中位106 Gy。
- GTV至PTV外扩<10 mm与≥10 mm相比,总生存和局部控制率无差异,放射性肺炎风险降低。
临床怎么用
- RTRT引导SBRT可用于I-IIA期周围型NSCLC,尤其适合高龄患者(中位年龄78岁)。
- 在RTRT追踪下,可考虑将GTV至PTV外扩降至<10 mm以减少放射性肺炎,但需前瞻性研究确认。
局限性
- 本研究为回顾性多中心分析,非前瞻性设计。
- 原文未报告局部控制率的具体数值及多因素分析中女性有利预测因素的效应量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the clinical outcomes of stage I and IIA non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT) using a real-time tumor-tracking radiotherapy (RTRT) system. MATERIALS AND METHODS: Patterns-of-care in SBRT using RTRT for histologically proven, peripherally located, stage I and IIA NSCLC was retrospectively investigated in four institutions by an identical clinical report format. Patterns-of-outcomes was also investigated in the same manner. RESULTS: From September 2000 to April 2012, 283 patients with 286 tumors were identified. The median age was 78 years (52-90) and the maximum tumor diameters were 9 to 65 mm with a median of 24 mm. The calculated biologically effective dose (10) at the isocenter using the linear-quadratic model was from 66 Gy to 126 Gy with a median of 106 Gy. With a median follow-up period of 28 months (range 0-127), the overall survival rate for the entire group, for stage IA, and for stage IB + IIA was 75%, 79%, and 65% at 2 years, and 64%, 70%, and 50% at 3 years, respectively. In the multivariate analysis, the favorable predictive factor was female for overall survival. There were no differences between the clinical outcomes at the four institutions. Grade 2, 3, 4, and 5 radiation pneumonitis was experienced by 29 (10.2%), 9 (3.2%), 0, and 0 patients. The subgroup analyses revealed that compared to margins from gross tumor volume (GTV) to planning target volume (PTV) ≥ 10 mm, margins < 10 mm did not worsen the overall survival and local control rates, while reducing the risk of radiation pneumonitis. CONCLUSIONS: This multi-institutional retrospective study showed that the results were consistent with the recent patterns-of-care and patterns-of-outcome analysis of SBRT. A prospective study will be required to evaluate SBRT using a RTRT system with margins from GTV to PTV < 10mm.
引用
- Katoh N, Soda I, Tamamura H, et al. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. Radiat Oncol. 2017. PMID: 28057036. doi:10.1186/s13014-016-0742-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。